PD-1 Antibody
<p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>
... example, PD-1 inhibitors, has two special ...Second, PD-1 inhibitors and other immunotherapy methods make patients with malignant tumor durable ...with PD-1 antibody ...
9
Fundamental effects of PD-1 antibody on the body: a brief report
... with anti-PD-1-related pneumonitis, one of whom died 4 weeks after the diagnosis of pneumonitis. The onset of their pneumonitis occurred 7.4–24.3 months after the initiation of the therapy. The only ...
5
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
... of 1, 3, and 10 mg/kg Q2W, and in both acral (1 CR and 2 PR) and mucosal (1 PR) ...high PD-L1 ex- pression and abundant TILs, regardless of tumor histology subtypes, indicating the ...
15
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy
... or PD-1/PD-L1 interaction blockade, results in sig- nificant decrease of Treg cells and MDSC in both spleens and tumors of treated ...with PD-1/PD-L1 inter- action blockade with ...
9
Immunotherapy for lethal prostate cancer.
... death 1 (PD-1) blocking agents have become crucial components of the treatment of deadly diseases such as metastatic lung cancer and melanoma, but have also changed the treatment paradigm in urologic ...
7
Phosphatidylserine targeting antibodies augment the anti tumorigenic activity of anti PD 1 therapy by enhancing immune activation and downregulating pro oncogenic factors induced by T cell checkpoint inhibition in murine triple negative breast cancers
... and PD-1 to contribute to an immunosuppressive tumor microenvironment, we sought to determine whether blocking recognition of PS and PD-1 alone and in combination are effective therapies in BC ...
14
Preliminary Comparison of Antibodies in Rabbit Serum from Secretory Human PD-1, Transmembrane Human PD-1 and Its Cell Membrane Enrichment
... Human PD-1 antibody is a method for treating tumors, which can block the interaction between PD-L1 and PD-1 to maintain the activation state of T lymphocytes that destroy ...
11
<p>Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report</p>
... Abstract: Advanced gastric cancer (AGC) is dif fi cult to treat with poor prognosis. Despite various possible treatments, the median survival time of such patients remains unsatisfactory. Therefore, new therapeutic ...
8
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
... death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal cell carcinoma ...
5
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
... therapeutic PD-1 antibody-bound subset, (2) upregulation of TIM-3 was only detected in tumour-bearing lungs but not in sentinel lymph nodes and peripheral blood, (3) TIM-3 positivity was significantly ...
10
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
... of PD-1 positive (+) TILs in cancer ...of PD-1(+) TILs were significantly associated with prolonged disease-free survival of pulmonary squamous cell carcinoma (SqCC) patients ...of ...
12
Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
... + PD-1 + lymphocyte were co-cultured with K7M2 ...anti-PD-1 antibody (Anti-PD-1), cis- platin (Cis; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and ...
11
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
... with PD-L1/ PD-1 monoclonal antibody therapy showed a pattern of rapid disease ...the PD-1/PD-L1 axis mediated inherent func- tions in the tumor cells and that the ...
13
Precision medicine becomes reality—tumor type-agnostic therapy
... 5. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, ...
7
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
... A total of 154 (124 males and 30 females) patients were included in the study. The median age was 55 years (range, 37–48 years). The median length of the tumor was 5 cm (range, 2–10 cm). Tumor locations were upper ...
12
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... demonstrated PD-L1 expression on tumor cells, and 33/40 (82%) demonstrated PD-L1 expression on tumor-infiltrating lymphocytes (TIL) and associated ...stroma. PD-1 expression was seen on ...
5
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
... of PD-L1, PD-1, CD3 and CD8 by immunohistochemistry ...for PD-L1 and PD-1 was performed by boiling slides in a pressure cooker for 5 min in Universal HIER retrieval agent (ab ...
11
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
... Finally, despite the unique aspects of TET biology, a few observations similar to ours have been described in non-thymic cancers such as a broadening of the TCR repertoire at 2 weeks post-initiation of treatment and ...
12
<p>Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer</p>
... therapy, PD-L1 expression may also be related to the prog- nosis of NSCLC patients according to recent ...and PD-L1 expression in them, fi nding that in the 41 initial treated NSCLC patients, patients with ...
10
Enhanced upper genital tract pathologies by blocking Tim 3 and PD L1 signaling pathways in mice intravaginally infected with Chlamydia muridarum
... [22]. PD-1 is an inducible molecule on activated T and B lymphocytes and plays a critical role in controlling lymphocyte activation and maintaining peripheral tolerance ...[19,23]. PD-L1, the primary ...
10